Abstract
Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and was often found to be deleted in hepatocellular carcinoma (HCC).
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria. Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found to play a pivotal role in regulating DLC-1. Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms linked to DLC-1 remain undefined.Keywords: DLC-1, tumor suppressor, RhoGAP activity, biomarker, GTPase, therapeutic target.
Anti-Cancer Agents in Medicinal Chemistry
Title:The Role of Tumor Suppressor DLC-1: Far From Clear
Volume: 17 Issue: 7
Author(s): Xu Liu, Yao-Jie Pan, Jun-Nian Zheng*Dong-Sheng Pei*
Affiliation:
- Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu,China
- Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu,China
Keywords: DLC-1, tumor suppressor, RhoGAP activity, biomarker, GTPase, therapeutic target.
Abstract: Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and was often found to be deleted in hepatocellular carcinoma (HCC).
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria. Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found to play a pivotal role in regulating DLC-1. Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms linked to DLC-1 remain undefined.Export Options
About this article
Cite this article as:
Liu Xu, Pan Yao-Jie, Zheng Jun-Nian*, Pei Dong-Sheng*, The Role of Tumor Suppressor DLC-1: Far From Clear, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520616666160907142754
DOI https://dx.doi.org/10.2174/1871520616666160907142754 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Recent Progress in Small Molecular Inhibitors of DNA Gyrase
Current Medicinal Chemistry Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Design, Synthesis and Antitumor Activity of Quinazoline Derivatives Bearing 2,3-Dihydro-indole or 1,2,3,4-Tetrahydroquinoline
Letters in Drug Design & Discovery The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease
Mini-Reviews in Medicinal Chemistry AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
Current Medicinal Chemistry Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery An Overview of Innovations in Analysis and Beneficial Health Effects of Wine Polyphenols
Mini-Reviews in Medicinal Chemistry Editorial Review of 2012
Current Radiopharmaceuticals Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Expanding the Biotherapeutics Realm via miR-34a: “Potent Clever Little” Agent in Breast Cancer Therapy
Current Pharmaceutical Biotechnology